dc.date.accessioned | 2023-07-12T08:57:27Z | |
dc.date.available | 2023-07-12T08:57:27Z | |
dc.date.created | 2023-04-11T15:01:21Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Karasik, Avraham Lanzinger, Stefanie Chia-Hui Tan, Elise Yabe, Daisuke Kim, Dae Jung Sheu, Wayne H-H Melzer-Cohen, Cheli Holl, Reinhard W. Ha, Kyoung Hwa Khunti, Kamlesh Zaccardi, Francesco Subramanian, Anuradhaa Nirantharakumar, Krishnarajah Nyström, Thomas Niskanen, Leo Linnemann Jensen, Majken Hoti, Fabian Klement, Riho Déruaz-Luyet, Anouk Kyaw, Moe H. Koeneman, Lisette Vistisen, Dorte Carstensen, Bendix Halvorsen, Sigrun Langslet, Gisle Fazeli Farsani, Soulmaz Patorno, Elisabetta Núñez, Júlio . Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes & Metabolism. 2023, 49(2) | |
dc.identifier.uri | http://hdl.handle.net/10852/102728 | |
dc.description.abstract | Background
Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.
Methods
The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014–2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 diabetes initiating empagliflozin were 1:1 propensity score matched to patients initiating dipeptidyl peptidase-4 inhibitors. Primary endpoints included hospitalization for heart failure, all-cause mortality, myocardial infarction and stroke. Other cardiovascular, renal, and safety outcomes were examined.
Findings
Among 83,946 matched patient pairs, (0·7 years overall mean follow-up time), initiation of empagliflozin was associated with lower risk of hospitalization for heart failure compared to dipeptidyl peptidase-4 inhibitors (Hazard Ratio 0·70; 95% CI 0.60 to 0.83). Risks of all-cause mortality (0·55; 0·48 to 0·63), stroke (0·82; 0·71 to 0·96), and end-stage renal disease (0·43; 0·30 to 0·63) were lower and risk for myocardial infarction, bone fracture, severe hypoglycemia, and lower-limb amputation were similar between initiators of empagliflozin and dipeptidyl peptidase-4 inhibitors. Initiation of empagliflozin was associated with higher risk for diabetic ketoacidosis (1·97; 1·28 to 3·03) compared to dipeptidyl peptidase-4 inhibitors. Results were consistent across continents and regions.
Interpretation
Results from this EMPRISE Europe and Asia study complements previous clinical trials and real-world studies by providing further evidence of the beneficial cardiorenal effects and overall safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | |
dc.title.alternative | ENEngelskEnglishEmpagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | |
dc.type | Journal article | |
dc.creator.author | Karasik, Avraham | |
dc.creator.author | Lanzinger, Stefanie | |
dc.creator.author | Chia-Hui Tan, Elise | |
dc.creator.author | Yabe, Daisuke | |
dc.creator.author | Kim, Dae Jung | |
dc.creator.author | Sheu, Wayne H-H | |
dc.creator.author | Melzer-Cohen, Cheli | |
dc.creator.author | Holl, Reinhard W. | |
dc.creator.author | Ha, Kyoung Hwa | |
dc.creator.author | Khunti, Kamlesh | |
dc.creator.author | Zaccardi, Francesco | |
dc.creator.author | Subramanian, Anuradhaa | |
dc.creator.author | Nirantharakumar, Krishnarajah | |
dc.creator.author | Nyström, Thomas | |
dc.creator.author | Niskanen, Leo | |
dc.creator.author | Linnemann Jensen, Majken | |
dc.creator.author | Hoti, Fabian | |
dc.creator.author | Klement, Riho | |
dc.creator.author | Déruaz-Luyet, Anouk | |
dc.creator.author | Kyaw, Moe H. | |
dc.creator.author | Koeneman, Lisette | |
dc.creator.author | Vistisen, Dorte | |
dc.creator.author | Carstensen, Bendix | |
dc.creator.author | Halvorsen, Sigrun | |
dc.creator.author | Langslet, Gisle | |
dc.creator.author | Fazeli Farsani, Soulmaz | |
dc.creator.author | Patorno, Elisabetta | |
dc.creator.author | Núñez, Júlio | |
cristin.unitcode | 185,53,11,10 | |
cristin.unitname | Hjertemedisinsk avdeling | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2140046 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Diabetes & Metabolism&rft.volume=49&rft.spage=&rft.date=2023 | |
dc.identifier.jtitle | Diabetes & Metabolism | |
dc.identifier.volume | 49 | |
dc.identifier.issue | 2 | |
dc.identifier.pagecount | 0 | |
dc.identifier.doi | https://doi.org/10.1016/j.diabet.2022.101418 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1262-3636 | |
dc.type.version | PublishedVersion | |
cristin.articleid | 101418 | |